Search
AC Immune SA
ACIUAdd to Watchlist
2.660USD
-0.170-6.01%
Close 09-24 16:00（ET）
270.71MMarket Cap
LossP/E TTM
About AC Immune SA Company
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
AC Immune SA Profile
Ticker SymbolACIU
Company nameAC Immune SA
IPO dateSep 23, 2016
CEOPfeifer (Andrea)
Number of employees133
Security typeOrdinary Share
Fiscal year-endSep 23
AddressEPFL Innovation Park
CityLAUSANNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountrySwitzerland
Postal code1015
Phone41213459121
Websitehttps://www.acimmune.com/
Ticker SymbolACIU
IPO dateSep 23, 2016
CEOPfeifer (Andrea)
Company Executives of AC Immune SA
Name
Name/Position
Position
Shareholding
Change
Prof. Dr. Andrea Pfeifer, Ph.D.
Prof. Dr. Andrea Pfeifer, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
3.41M
-0.29%
Prof. Dr. Andrea Pfeifer, Ph.D.
Prof. Dr. Andrea Pfeifer, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
3.41M
-0.29%
Prof. Dr. Andrea Pfeifer, Ph.D.
Prof. Dr. Andrea Pfeifer, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
3.41M
-0.29%
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
75.37K
+49.52%
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
75.37K
+49.52%
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
75.37K
+49.52%
Prof. Carl June, M.D.
Prof. Carl June, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
75.27K
+22.01%
Prof. Carl June, M.D.
Prof. Carl June, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
75.27K
+22.01%
Prof. Carl June, M.D.
Prof. Carl June, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
75.27K
+22.01%
Mr. Piergiorgio Donati
Mr. Piergiorgio Donati
Chief Technical Operations Officer
Chief Technical Operations Officer
74.24K
+38.31%
View more
Name
Name/Position
Position
Shareholding
Change
Prof. Dr. Andrea Pfeifer, Ph.D.
Prof. Dr. Andrea Pfeifer, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
3.41M
-0.29%
Prof. Dr. Andrea Pfeifer, Ph.D.
Prof. Dr. Andrea Pfeifer, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
3.41M
-0.29%
Prof. Dr. Andrea Pfeifer, Ph.D.
Prof. Dr. Andrea Pfeifer, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
3.41M
-0.29%
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
75.37K
+49.52%
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
75.37K
+49.52%
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
75.37K
+49.52%
FAQs
Who are the top five shareholders of AC Immune SA?
The top five shareholders of AC Immune SA are: Prof. Dr. Andrea Pfeifer, Ph.D.
How many institutions hold shares of AC Immune SA (ACIU)?
As of 2026Q1, 106 institutions hold shares of AC Immune SA, with a combined market value of approximately 26.78M, accounting for 26.32% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1698579.00.